Aethlon Medical reports biomarker shifts in second cohort of Hemopurifier cancer trial
AEMD•Second cohort shows similar biomarker shifts
Aethlon Medical reported similar biomarker shifts in cohort 2 of its Australian oncology feasibility study of Hemopurifier in advanced solid tumors.
- Observed reductions in tumor-related extracellular vesicles, including PD-L1-positive vesicles, with increases in T-cell measures that generally persisted through eight weeks.
- Enrollment continues in the third and final cohort; an independent statistical analysis is planned once all cohorts are completed to assess a dose-response signal.
- Results remain preliminary; the study is not designed to show clinical efficacy or patient-outcome benefit.
